Prague Med. Rep. 2023, 124, 33-39
https://doi.org/10.14712/23362936.2023.3
Screening for SARS-COV-2 Using RT-qPCR in Patients with Hematologic Neoplasms Receiving Chemotherapy
References
1. American Society of Hematology (2022) COVID-19 resources. Accessed June 1, 2022. Available at: https://www.hematology.org/covid-19
2. 2020) Screening strategies for COVID-19 in patients with hematologic malignancies. Front. Oncol. 10, 1267.
< , T., Samra, B., Dercle, L., Rassy, E., Kattan, J., Ghosn, M., Houot, R., Ammari, S. (https://doi.org/10.3389/fonc.2020.01267>
3. 2021) Clinical characteristics and evolution of hematological patients and COVID-19 in Argentina: A report from the Argentine Society of Hematology. Medicina 81(4), 536–545.
, A. L., García, M. J., Martinez Rolón, J., Olmedo, J., Laviano, J., Burgos, R., Caeiro, G., Remaggi, G., Raña, P., Paoletti, M., González, C. M., Fernández, I., Pavlovsky, A., Perusini, M. A., Rodriguez, A., Guanchiale, L., Carvani, A., Mandrile, L., Figueroa, F., Vicente Reparaz, A., Fragapane Mathus, P. N., Garate, G., Fauque, M. E., Kantor, G., Cruset, S., Gonzalez Lorch, J. S., Szelagowski, M., Giarini, M. P., Oliveira, N., García, M. C., Ventriglia, M. V., Pereyra, P. H., Gutierrez, D. R., Kusminsky, G., Troccoli, J., Freitas, M. J., Cranco, S., Del V Sanchez, N., Rey, J., Funes, M. E., Jarchum, S., Freue, J., Miroli, A., Guerrero, O., López Ares, L., Campestri, R., Bove, V., Salinas, G. N., Cabrejo, M., Milone, J. H., Zabaljauregui, S., Gotta, D., Dupont, J. C., Stemmelin, G. (
4. European Hematology Association (2022) COVID-19 and Hematology Information Center. Expert opinion for specific hematologic malignancies. Accessed June 6, 2022. Available at: https://ehaweb.org/covid-19/covid-19-recommendations/recommendations-for-specific-hematologic-malignancies/
5. 2020) Acute leukemia in the time of COVID-19. Leuk. Res. 92, 106353.
< , M., Carr Klappert, J., Spertini, O., Blum, S. (https://doi.org/10.1016/j.leukres.2020.106353>
6. 2022) Early remdesivir to prevent progression to severe Covid-19 in outpatients. N. Engl. J. Med. 386(4), 305–315.
< , R. L., Vaca, C. E., Paredes, R., Mera, J., Webb, B. J., Perez, G., Oguchi, G., Ryan, P., Nielsen, B. U., Brown, M., Hidalgo, A., Sachdeva, Y., Mittal, S., Osiyemi, O., Skarbinski, J., Juneja, K., Hyland, R. H., Osinusi, A., Chen, S., Camus, G., Abdelghany, M., Davies, S., Behenna-Renton, N., Duff, F., Marty, F. M., Katz, M. J., Ginde, A. A., Brown, S. M., Schiffer, J. T., Hill, J. A.; GS-US-540-9012 (PINETREE) Investigators (https://doi.org/10.1056/NEJMoa2116846>
7. Infectious Disease Society of America (2022) IDSA and AMP joint statement on the use of SARS-CoV-2 PCR cycle threshold (Ct) values for clinical decision-making. Accessed June 6, 2022. Available at: https://www.idsociety.org/globalassets/idsa/public-health/covid-19/idsa-amp-statement.pdf
8. 2020) Viral RNA load as determined by cell culture as a management tool for discharge of SARS-CoV-2 patients from infectious disease wards. Eur. J. Clin. Microbiol. Infect. Dis. 39(6), 1059–1061.
< , B., Le Bideau, M., Andreani, J., Hoang, V. T., Grimaldier, C., Colson, P., Gautret, P., Raoult, D. (https://doi.org/10.1007/s10096-020-03913-9>
9. 2020) COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: A prospective cohort study. Lancet Oncol. 21(10), 1309–1316.
< , L. Y. W., Cazier, J. B., Starkey, T., Briggs, S. E. W., Arnold, R., Bisht, V., Booth, S., Campton, N. A., Cheng, V. W. T., Collins, G., Curley, H. M., Earwaker, P., Fittall, M. W., Gennatas, S., Goel, A., Hartley, S., Hughes, D. J., Kerr, D., Lee, A. J. X., Lee, R. J., Lee, S. M., Mckenzie, H., Middleton, C. P., Murugaesu, N., Newsom-Davis, T., Olsson-Brown, A. C., Palles, C., Powles, T., Protheroe, E. A., Purshouse, K., Sharma-Oates, A., Sivakumar, S., Smith, A. J., Topping, O., Turnbull, C. D., Várnai, C., Briggs, A. D. M., Middleton, G., Kerr, R.; UK Coronavirus Cancer Monitoring Project Team (https://doi.org/10.1016/S1470-2045(20)30442-3>
10. 2021) SARS-CoV-2 testing for asymptomatic patients with cancer prior and during treatment: A single centre experience. Curr. Oncol. 28(1), 278–282.
< , N., Tahmasebi, H., Leahey, A., Boudreau, A., Thawer, A., Stewart, J., Reason, P., Albright, K., Leis, J. A., Katz, K., Cheung, M. C., Singh, S. (https://doi.org/10.3390/curroncol28010032>
11. 2020) Clinical screening for COVID-19 in asymptomatic patients with cancer. JAMA Netw. Open 3(9), e2023121.
< , M. A., Mayer, S., Emlen, F., Sholle, E., Christos, P., Cushing, M., Hidalgo, M. (https://doi.org/10.1001/jamanetworkopen.2020.23121>
12. 2020) Outcomes of patients with hematologic malignancies and COVID-19: A report from the ASH Research Collaborative Data Hub. Blood Adv. 4(23), 5966–5975.
< , W. A., Neuberg, D. S., Thompson, J. C., Tallman, M. S., Sekeres, M. A., Sehn, L. H., Anderson, K. C., Goldberg, A. D., Pennell, N. A., Niemeyer, C. M., Tucker, E., Hewitt, K., Plovnick, R. M., Hicks, L. K. (https://doi.org/10.1182/bloodadvances.2020003170>
13. World Health Organization (2022) Recommendations for national SARS-CoV-2 testing strategies and diagnostic capacities. Interim guidance 25 June 2021. Accessed June 6, 2022. Available at: https://apps.who.int/iris/bitstream/handle/10665/342002/WHO-2019-nCoV-lab-testing-2021.1-eng.pdf?sequence=1&isAllowed=y
14. World Health Organization (2022) WHO Coronavirus (COVID-19) Dashboard. Accessed June 6, 2022. Available at: https://covid19.who.int/
15. 2020) An analysis of cancer patients with asymptomatic infection of SARS-CoV-2 in a cancer center in Wuhan, China. Ann. Oncol. 31(10), 1420–1422.
< , P., Zeng, R., Duan, Y. R., Zhang, Y., Kuang, X. N., Zhang, H. F., Wei, S. Z. (https://doi.org/10.1016/j.annonc.2020.07.008>